The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Improving Bone Mineral Density: Risedronate vs. Denosumab

Improving Bone Mineral Density: Risedronate vs. Denosumab

March 2, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—In a post-hoc analysis, treatment with denosumab proved superior to risedronate for increasing lumbar spine and total hip bone mineral density (BMD) in patients with rheumatoid arthritis (RA) and glucocorticoid-induced osteoporosis.1 These data were presented by Jonathan Adachi, MD, professor of medicine, McMaster University, and staff rheumatologist at St. Joseph’s Healthcare, Hamilton, Ontario, Canada, during ACR Convergence 2021.

You Might Also Like
  • Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Supplemental Application for Denosumab Goes to FDA
Explore This Issue
April 2022
Also By This Author
  • Baricitinib Has Promising Clinical Trial Results for Treating RA

The original phase 3 study was an active, controlled, double-blind, double-dummy study that showed treatment with denosumab was superior to risedronate for BMD increases in patients with osteoporosis who were treated with glucocorticoids (NCT01575873).2 The post-hoc analysis included patients who were either starting at least 7.5 mg of prednisone daily or the equivalent for less than three months prior to screening or continuing at least 7.5 mg of prednisone treatment (glucocorticoid) daily or the equivalent at least three months prior to screening.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients were randomly assigned to receive either 5 mg of risedronate daily or 60 mg of denosumab every six months for 24 months. Patients also received at least 1,000 mg of calcium and 800 international units of vitamin D daily.

The primary outcome was a greater mean difference in the percent change from baseline in the lumbar spine BMD, determined by dual x-ray absorptiometry (DXA), at month 12 for denosumab compared with risedronate. Secondary objectives obtained at months 12 and 24 included comparisons of the mean percent change from baseline in lumbar spine, total hip and femoral neck BMD, as well as in serum type 1 collagen C‑telopeptide (sCTX) and procollagen type 1 N-telopeptide (P1NP). The study also assessed safety.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Results

The post-hoc analysis included 300 patients with RA: 143 were treated with denosumab and 157 were treated with risedronate. The mean prednisone-equivalent doses were around 10.5 mg (± 4.2 to 4.8) at baseline for both study groups. At 12 months, a significant mean difference (95% confidence interval) in the percent change from baseline in BMD was observed between the two groups: 1.8% for the lumbar spine, 1.9% for the total hip and 1.5% for the femoral neck. At month 24, the mean changes for denosumab were: 3.2% for the lumbar spine, 2.3% for the total hip and 2.1% for the femoral neck.

During the first five months of treatment, sCTX and P1NP levels significantly decreased in patients treated with denosumab compared with those treated with risedronate. However, at months 12 and 24, no significant differences were observed in the percent change from baseline between the two treatment groups.

Pages: 1 2 | Single Page

Filed Under: ACR Convergence, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2021, bone mineral density (BMD), denosumab, Glucocorticoids, Osteoporosis, risedronateIssue: April 2022

You Might Also Like:
  • Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Supplemental Application for Denosumab Goes to FDA
  • FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)